News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
70 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38485)
2025 (25273)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3635)
June (2415)
July (2091)
August (2652)
September (2458)
October (473)
Day
2 (202)
3 (126)
4 (116)
5 (123)
6 (51)
9 (127)
10 (95)
11 (131)
12 (128)
13 (61)
16 (159)
17 (116)
18 (142)
19 (71)
20 (36)
23 (191)
24 (140)
25 (137)
26 (112)
27 (81)
30 (70)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
Day
2
3
4
5
6
9
10
11
12
13
16
17
18
19
20
23
24
25
26
27
30
FDA
FDA’s AI Rollout Raises Questions Around Readiness, Legality
The FDA’s clunky launch of Elsa, an AI tool to increase efficiency, has sparked concern from agency employees and outside experts.
June 30, 2025
·
6 min read
·
Natalia Mesa
Influenza
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would refile following data from this Phase III trial.
June 30, 2025
·
2 min read
·
Tristan Manalac
Government
100+ CEOs, Biopharma Leaders Sound Alarm on ‘Catastrophic’ Health Cuts
In an open letter addressing the Trump administration’s proposed budget cuts to HHS, the executives urged Congress to continue “robust federal funding” for scientific research, which they say will help maintain U.S. biotech leadership globally.
June 30, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
INmune Crashes After Missing Cognitive Target in Phase II Alzheimer’s Trial
Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of its TNF inhibitor in patients with early Alzheimer’s disease who have at least two biomarkers of inflammation.
June 30, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Alzheimer’s Deals Surged 780% After Leqembi, Kisunla Broke Approval Stalemate
The rise of monoclonal antibodies brought back hope for stalling or reversing the devastating neurodegenerative disease. Big Pharma has taken notice with a handful of high-value deals, GlobalData reports.
June 30, 2025
·
2 min read
·
Annalee Armstrong
Layoffs
BMS Continues New Jersey Layoffs, Bringing Yearly Total to Nearly 900
BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April 2024 as part of its cost-cutting measures.
June 30, 2025
·
1 min read
·
Angela Gabriel
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’
in vivo
edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
Cancer
Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test
In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though analysts pledged to wait for more data on safety and tolerability before assessing the drug.
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
Approvals
Moderna, Merck, UroGen, Score RSV and Cancer Nods in June
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an approval in bladder cancer, and more key regulatory nods from the past month.
June 30, 2025
·
9 min read
·
Tristan Manalac
Layoffs
Sage Sacks Entire Staff After Supernus Buyout
As of Apr. 22, Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks after Maryland’s Supernus Pharmaceuticals acquired Sage for up to $795 million.
June 30, 2025
·
1 min read
·
Tristan Manalac
1 of 7
Next